amantadine has been researched along with Multiple Sclerosis in 66 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Multiple Sclerosis: An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 9.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 9.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 9.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures." | 9.09 | Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 9.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| "Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0." | 9.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six." | 9.06 | Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988) |
| "We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo." | 9.05 | Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985) |
| "The efficacy of amantadine in reducing fatigue in people with MS is poorly documented, as well as its tolerability." | 8.84 | Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007) |
| "Amantadine treatment is overall well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and there is insufficient evidence to make recommendations to guide prescribing." | 8.82 | Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003) |
| "Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis." | 8.31 | Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023) |
| "To report a patient with secondary progressive multiple sclerosis (SPMS) who developed late-onset side effects of amantadine which were initially felt to represent a progression of her SPMS." | 8.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research." | 7.79 | Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013) |
| "The authors report the successful use of Descemet's stripping automated endothelial keratoplasty (DSAEK) to treat a 45-year-old woman with amantadine-associated corneal edema." | 7.76 | Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. ( Dupps, WJ; Hood, CT; Langston, RH; Schoenfield, LR, 2010) |
| "Amantadine can cause corneal edema that begins a few months to several years after institution of therapy, and the edema can occur even in a corneal graft." | 7.74 | Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. ( Galor, A; Hollyfield, JG; Jeng, BH; Langston, RH; Lee, MS; McMahon, JT; Meisler, DM; Schoenfield, L, 2008) |
| " Numeric dose response was seen for some secondary efficacy outcomes and adverse events." | 7.11 | A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. ( Cameron, MH; Cohen, JA; Elfont, R; Goldman, MD; Goodman, AD; Johnson, R; Llorens, L; Miller, AE; Patni, R; Rollins, A, 2022) |
| "Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed." | 7.01 | Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021) |
| " The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia." | 6.90 | Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019) |
| "Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment." | 6.66 | Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989) |
| "Acupuncture combined with amantadine and routine care compared with amantadine and routine care alone appears to be an effective short-term treatment for reducing fatigue and enhancing quality of life, including physical function and mental status, in patients with RRMS." | 5.69 | Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. ( Kazemi, AH; Khodaie, F; Naser Moghadasi, A; Zhao, B, 2023) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 5.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "We present a case of amantadine-induced coma in a patient with multiple sclerosis and end-stage renal disease." | 5.29 | Amantadine-induced coma. ( Ito, V; Macchio, GJ; Sahgal, V, 1993) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 5.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 5.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 5.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures." | 5.09 | Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 5.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| "Amantadine-treated patients showed a significantly greater reduction in fatigue, as measured by the MS-FS, than did patients treated with placebo (p = 0." | 5.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six." | 5.06 | Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988) |
| "We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo." | 5.05 | Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985) |
| " Search terms included multiple sclerosis, fatigue, medication treatments, amantadine, modafinil, aspirin, acetyl-l-carnitine, pemoline, 4-aminopyridine and randomized controlled trial (RCT)." | 4.95 | Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| " In the completed study, adult patients with relapsing-remitting and secondary progressive MS were exposed to both acetyl L-carnitine 2 grams daily and amantadine 200 mg daily The effects of carnitine on fatigue are unclear." | 4.88 | Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "The efficacy of amantadine in reducing fatigue in people with MS is poorly documented, as well as its tolerability." | 4.84 | Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007) |
| "Amantadine treatment is overall well tolerated, however its efficacy in reducing fatigue in people with MS is poorly documented and there is insufficient evidence to make recommendations to guide prescribing." | 4.82 | Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003) |
| " Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term." | 4.80 | Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000) |
| "Amantadine hydrochloride is a well-known antiviral agent that has been used for the prevention of influenza A2, the treatment of Parkinson disease, and, more recently, multiple sclerosis." | 4.78 | Fetal outcome following intrauterine amantadine exposure. ( Koren, G; Levy, M; Pastuszak, A, 1991) |
| "Amantadine is an N-methyl-d-aspartate receptor agonist with secondary dopaminergic activity that is used to treat Parkinson's disease-related dyskinesia and to treat fatigue in multiple sclerosis." | 4.31 | Amantadine toxicity causing visual hallucinations. ( Barbara, JM; Pace, A, 2023) |
| "To report a patient with secondary progressive multiple sclerosis (SPMS) who developed late-onset side effects of amantadine which were initially felt to represent a progression of her SPMS." | 4.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research." | 3.79 | Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013) |
| "The authors report the successful use of Descemet's stripping automated endothelial keratoplasty (DSAEK) to treat a 45-year-old woman with amantadine-associated corneal edema." | 3.76 | Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty. ( Dupps, WJ; Hood, CT; Langston, RH; Schoenfield, LR, 2010) |
| "Amantadine can cause corneal edema that begins a few months to several years after institution of therapy, and the edema can occur even in a corneal graft." | 3.74 | Amantadine-associated corneal edema potentially irreversible even after cessation of the medication. ( Galor, A; Hollyfield, JG; Jeng, BH; Langston, RH; Lee, MS; McMahon, JT; Meisler, DM; Schoenfield, L, 2008) |
| "In the last several years, amantadine has been increasingly prescribed for akinesia in Parkinson's disease and to combat fatigue associated with multiple sclerosis." | 3.73 | Amantadine-induced livedo reticularis: a report of two cases. ( Cook-Norris, RH; Hayes, BB; Miller, JL; Rodriguez, A; Zic, JA, 2006) |
| " Numeric dose response was seen for some secondary efficacy outcomes and adverse events." | 3.11 | A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. ( Cameron, MH; Cohen, JA; Elfont, R; Goldman, MD; Goodman, AD; Johnson, R; Llorens, L; Miller, AE; Patni, R; Rollins, A, 2022) |
| "Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed." | 3.01 | Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021) |
| " The most frequent adverse events (AEs) were dry mouth, constipation, and insomnia." | 2.90 | Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. ( Brown, TR; Chernoff, DN; Cohen, JA; Gudesblatt, M; Hunter, SF; Llorens, L; Patni, R; Ruby, AE; Souza-Prien, CJ; Thrower, BW, 2019) |
| "Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment." | 2.66 | Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is recognized as one of the most disabling and common symptoms of MS." | 2.44 | Treating fatigue. ( Hum, S; Lapierre, Y, 2007) |
| "Fatigue is the most common symptom of MS and is associated with a reduced quality of life." | 2.42 | Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Fatigue is a common symptom in patients with multiple sclerosis." | 2.40 | ['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999) |
| "Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms." | 2.38 | Update on multiple sclerosis therapy. ( Mitchell, G, 1993) |
| "Facing the outbreak of coronavirus disease 2019 (COVID-19) pandemic, there is an urgent need to find protective or curable drugs to prevent or to stop the course of the coronavirus SARS-CoV-2 infection." | 1.56 | Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. ( Grieb, P; Rejdak, K, 2020) |
| "The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue." | 1.34 | Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007) |
| "Fatigue is a common complaint in patients affected by multiple sclerosis." | 1.31 | [Therapeutic indications for managing symptoms: fatigue]. ( Waubant, E, 2001) |
| "We present a case of amantadine-induced coma in a patient with multiple sclerosis and end-stage renal disease." | 1.29 | Amantadine-induced coma. ( Ito, V; Macchio, GJ; Sahgal, V, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (13.64) | 18.7374 |
| 1990's | 12 (18.18) | 18.2507 |
| 2000's | 20 (30.30) | 29.6817 |
| 2010's | 13 (19.70) | 24.3611 |
| 2020's | 12 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Nourbakhsh, B | 3 |
| Bradley, L | 1 |
| Khodaie, F | 1 |
| Naser Moghadasi, A | 1 |
| Kazemi, AH | 1 |
| Zhao, B | 1 |
| Barbara, JM | 1 |
| Pace, A | 1 |
| Rocca, MA | 2 |
| Valsasina, P | 2 |
| Lamanna, MT | 1 |
| Colombo, B | 2 |
| Martinelli, V | 2 |
| Filippi, M | 2 |
| Rejdak, K | 2 |
| Grieb, P | 2 |
| Perez, DQ | 1 |
| Espiritu, AI | 1 |
| Jamora, RDG | 1 |
| Revirajan, N | 2 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 3 |
| Bourdette, D | 1 |
| Świątkiewicz, M | 1 |
| Prus, K | 1 |
| Cohen, JA | 2 |
| Cameron, MH | 1 |
| Goldman, MD | 1 |
| Goodman, AD | 1 |
| Miller, AE | 1 |
| Rollins, A | 1 |
| Llorens, L | 2 |
| Patni, R | 2 |
| Elfont, R | 1 |
| Johnson, R | 1 |
| Yang, TT | 1 |
| Wang, L | 1 |
| Deng, XY | 1 |
| Yu, G | 1 |
| Hunter, SF | 1 |
| Brown, TR | 1 |
| Gudesblatt, M | 1 |
| Thrower, BW | 1 |
| Souza-Prien, CJ | 1 |
| Ruby, AE | 1 |
| Chernoff, DN | 1 |
| Sulkowski, G | 1 |
| Dąbrowska-Bouta, B | 1 |
| Strużyńska, L | 1 |
| Ledinek, AH | 1 |
| Sajko, MC | 1 |
| Rot, U | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 2 |
| Santarnecchi, E | 1 |
| Rossi, S | 1 |
| Bartalini, S | 1 |
| Cincotta, M | 1 |
| Giovannelli, F | 1 |
| Tatti, E | 1 |
| Ulivelli, M | 1 |
| Naumann, GO | 1 |
| Schlötzer-Schrehardt, U | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 1 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Hood, CT | 1 |
| Langston, RH | 2 |
| Schoenfield, LR | 1 |
| Dupps, WJ | 1 |
| Tejani, AM | 1 |
| Wasdell, M | 1 |
| Spiwak, R | 1 |
| Rowell, G | 1 |
| Nathwani, S | 1 |
| Induruwa, I | 1 |
| Constantinescu, CS | 1 |
| Gran, B | 1 |
| Shaygannejad, V | 1 |
| Janghorbani, M | 1 |
| Ashtari, F | 1 |
| Zakeri, H | 1 |
| Foroughipour, M | 1 |
| Bahrami Taghanaki, HR | 1 |
| Saeidi, M | 1 |
| Khazaei, M | 1 |
| Sasannezhad, P | 1 |
| Shoeibi, A | 1 |
| Taus, C | 2 |
| Giuliani, G | 2 |
| Pucci, E | 2 |
| D'Amico, R | 2 |
| Solari, A | 2 |
| Bakshi, R | 1 |
| Tomassini, V | 1 |
| Pozzilli, C | 1 |
| Onesti, E | 1 |
| Pasqualetti, P | 1 |
| Marinelli, F | 1 |
| Pisani, A | 1 |
| Fieschi, C | 1 |
| Zifko, UA | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 2 |
| Boggild, M | 1 |
| Ford, H | 2 |
| Hayes, BB | 1 |
| Cook-Norris, RH | 1 |
| Miller, JL | 1 |
| Rodriguez, A | 1 |
| Zic, JA | 1 |
| Debouverie, M | 1 |
| Pittion, S | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Nicholas, R | 1 |
| Axelrod, S | 1 |
| Bielory, L | 1 |
| Branãs, P | 2 |
| Benito-León, J | 1 |
| Martínez-Martín, P | 1 |
| Frades, B | 1 |
| Martínez-Ginés, ML | 1 |
| de Andrés, C | 1 |
| Meca-Lallana, JE | 1 |
| Antigüedad, AR | 1 |
| Huete-Antón, B | 1 |
| Rodríguez-García, E | 1 |
| Ruiz-Martínez, J | 1 |
| Lapierre, Y | 1 |
| Hum, S | 1 |
| Jeng, BH | 1 |
| Galor, A | 1 |
| Lee, MS | 1 |
| Meisler, DM | 1 |
| Hollyfield, JG | 1 |
| Schoenfield, L | 1 |
| McMahon, JT | 1 |
| Krupp, LB | 3 |
| Coyle, PK | 2 |
| Doscher, C | 2 |
| Miller, A | 1 |
| Cross, AH | 1 |
| Jandorf, L | 1 |
| Halper, J | 1 |
| Johnson, B | 1 |
| Morgante, L | 1 |
| Grimson, R | 1 |
| Mitchell, G | 1 |
| Macchio, GJ | 1 |
| Ito, V | 1 |
| Sahgal, V | 1 |
| Geisler, MW | 1 |
| Sliwinski, M | 1 |
| Masur, DM | 1 |
| Poser, CM | 1 |
| Dulli, D | 1 |
| Schutta, H | 1 |
| Huete, B | 1 |
| Varona, L | 1 |
| Zimmermann, C | 1 |
| Hohlfeld, R | 1 |
| Sailer, M | 1 |
| Heinze, HJ | 1 |
| Schoenfeld, MA | 1 |
| Hauser, U | 1 |
| Smid, HG | 1 |
| Jordan, R | 1 |
| Fry-Smith, A | 1 |
| Burls, A | 1 |
| Hyde, C | 1 |
| Christodoulou, C | 1 |
| Chiba, S | 1 |
| Ito, M | 1 |
| Matsumoto, H | 1 |
| Levy, M | 1 |
| Pastuszak, A | 1 |
| Koren, G | 1 |
| Wiggs, JW | 1 |
| de Roin, S | 1 |
| Winters, S | 1 |
| Maciejek, Z | 1 |
| Cohen, RA | 1 |
| Fisher, M | 1 |
| Rosenberg, GA | 1 |
| Appenzeller, O | 1 |
| Plaut, GS | 1 |
| Schapira, M | 1 |
| Fog, T | 1 |
| Potvin, AR | 1 |
| Albers, JW | 1 |
| Repa, BS | 1 |
| Henderson, WG | 1 |
| Walker, JE | 1 |
| Stribley, RF | 1 |
| Tourtellotte, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
21 reviews available for amantadine and Multiple Sclerosis
| Article | Year |
|---|---|
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis.
Topics: Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis | 2020 |
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig | 2017 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Amantadine; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trial | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Amantadine for fatigue in multiple sclerosis.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Management of fatigue in patients with multiple sclerosis.
Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical | 2004 |
Multiple sclerosis.
Topics: Amantadine; Exercise Therapy; Glatiramer Acetate; Humans; Interferon-beta; Mitoxantrone; Multiple Sc | 2004 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
Multiple sclerosis.
Topics: Adrenal Cortex Hormones; Amantadine; Azathioprine; Glatiramer Acetate; Humans; Immunoglobulins, Intr | 2005 |
Amantadine for fatigue in multiple sclerosis.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros | 2007 |
Treating fatigue.
Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents | 2007 |
Update on multiple sclerosis therapy.
Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M | 1993 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; | 1999 |
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base | 2000 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
Fetal outcome following intrauterine amantadine exposure.
Topics: Adult; Amantadine; Animals; Embryonic and Fetal Development; Female; Follow-Up Studies; Humans; Mate | 1991 |
Amantadine hydrochloride: current and new uses.
Topics: Amantadine; Humans; Influenza, Human; Multiple Sclerosis; Parkinson Disease | 1990 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
20 trials available for amantadine and Multiple Sclerosis
| Article | Year |
|---|---|
Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial.
Topics: Acupuncture Therapy; Amantadine; Fatigue; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing- | 2023 |
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
Topics: Amantadine; Brain; Brain Mapping; Dopamine; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sc | 2023 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine.
Topics: 4-Aminopyridine; Amantadine; Brain; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sclerosis | 2021 |
A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment.
Topics: 4-Aminopyridine; Adult; Amantadine; Delayed-Action Preparations; Double-Blind Method; Humans; Multip | 2022 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum | 2018 |
Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Amantadine; Delayed-Action Preparations; Dopamine Agents; Double-Blind Method; Dyskines | 2019 |
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans | 2013 |
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.
Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross | 2012 |
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
Topics: Acetylcarnitine; Adult; Amantadine; Analgesics, Non-Narcotic; Analysis of Variance; Confidence Inter | 2004 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C | 1996 |
Amantadine influences cognitive processing in patients with multiple sclerosis.
Topics: Adult; Amantadine; Attention; Brain; Cognition; Dopamine Agents; Double-Blind Method; Evoked Potenti | 2000 |
Changes in visual evoked potentials in patients with multiple sclerosis treated with isoprinosine and amantadine.
Topics: Adolescent; Adult; Amantadine; Evoked Potentials, Visual; Female; Humans; Inosine Pranobex; Male; Mu | 1989 |
Amantadine treatment of fatigue associated with multiple sclerosis.
Topics: Adult; Amantadine; Circadian Rhythm; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis; | 1989 |
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.
Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me | 1987 |
Amantadine, fatigue, and multiple sclerosis.
Topics: Amantadine; beta-Endorphin; beta-Lipotropin; Disability Evaluation; Fatigue; Humans; Lactates; Lacti | 1988 |
Effectiveness of amantadine in reducing relapses in multiple sclerosis.
Topics: Adult; Amantadine; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; | 1987 |
Amantadine therapy for fatigue in multiple sclerosis.
Topics: Amantadine; Clinical Trials as Topic; Fatigue; Humans; Multiple Sclerosis | 1985 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
26 other studies available for amantadine and Multiple Sclerosis
| Article | Year |
|---|---|
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Risk Assessment | 2021 |
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
Topics: Amantadine; Disease Progression; Fatigue; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Ch | 2021 |
Amantadine toxicity causing visual hallucinations.
Topics: Amantadine; Antiparkinson Agents; Female; Hallucinations; Humans; Levodopa; Multiple Sclerosis | 2023 |
Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Amantadine; Asymptomatic Infections; Betacoronavirus; Co | 2020 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph | 2021 |
Amantadine for COVID-19.
Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis | 2021 |
Modulation of neurological deficits and expression of glutamate receptors during experimental autoimmune encephalomyelitis after treatment with selected antagonists of glutamate receptors.
Topics: Amantadine; Animals; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Excitatory | 2013 |
Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine.
Topics: Adult; Amantadine; Evoked Potentials, Motor; Fatigue; Female; Fingers; Humans; Male; Middle Aged; Mo | 2015 |
Amantadine-associated corneal edema.
Topics: Amantadine; Analgesics, Non-Narcotic; Bipolar Disorder; Corneal Edema; Dopamine Agents; Humans; Kera | 2009 |
Amantadine-associated corneal edema treated with descemet's stripping automated endothelial keratoplasty.
Topics: Amantadine; Automation; Corneal Edema; Descemet Stripping Endothelial Keratoplasty; Diagnosis, Diffe | 2010 |
Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Amantadine; Child; Drug Resistance; Fatigue; Female; H | 2013 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
Amantadine-induced livedo reticularis: a report of two cases.
Topics: Aged; Amantadine; Antiparkinson Agents; Diagnosis, Differential; Female; Humans; Leg; Middle Aged; M | 2006 |
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed | 2006 |
Beta2-agonists and paresthesias in multiple sclerosis.
Topics: Adrenergic beta-Agonists; Albuterol; Amantadine; Analgesics, Non-Narcotic; Androstadienes; Aromatase | 2007 |
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami | 2007 |
Amantadine-associated corneal edema potentially irreversible even after cessation of the medication.
Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Bipolar Disorder; Corneal Edema; Dopamine Agents; Femal | 2008 |
Amantadine-induced coma.
Topics: Adult; Amantadine; Coma; Humans; Kidney Failure, Chronic; Male; Multiple Sclerosis | 1993 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis | 1996 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline | 1996 |
[Insomnia during treatment with amantadine].
Topics: Adult; Amantadine; Dopamine Agents; Fatigue; Humans; Male; Multiple Sclerosis; Sleep Initiation and | 1997 |
[Therapeutic indications for managing symptoms: fatigue].
Topics: Amantadine; Aminopyridines; Double-Blind Method; Fatigue; Humans; Multiple Sclerosis; Randomized Con | 2001 |
Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis.
Topics: Adult; Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pain | 1992 |
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis.
Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki | 1991 |
Treating multiple sclerosis with amantadine hydrochloride.
Topics: Amantadine; Diplopia; Humans; Male; Middle Aged; Multiple Sclerosis; Speech Disorders; Vertigo | 1974 |
[Letter: Amantadine treatment in disseminated sclerosis].
Topics: Amantadine; Humans; Multiple Sclerosis | 1974 |